<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347704">
  <stage>Registered</stage>
  <submitdate>15/02/2012</submitdate>
  <approvaldate>23/03/2012</approvaldate>
  <actrnumber>ACTRN12612000336886</actrnumber>
  <trial_identification>
    <studytitle>Isofurans Production under Hyperbaric conditions: an observational study in patients with osteonecrosis secondary to radiotherapy</studytitle>
    <scientifictitle>Serum Isofurans trend levels in patients with osteonecrosis undergoing hyperbaric therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Oxidative stress</healthcondition>
    <healthcondition>Examination of Isofurans</healthcondition>
    <healthcondition>Osteonecrosis</healthcondition>
    <healthcondition>Hyperbaric therapy</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Measuring Isofurans compound levels in serum during hyperbaric treatment. We will be taking 7 blood samples (through one peripheral cannula) during the first hyperbaric treatment of a patient with radio-osteonecrosis. The serum levels of Isofurans (and other routine bloods such as a full blood picture / urea and electrolytes) will be recorded. The duration of this study is expected to be 12 months from beginning of data collection (i.e. finish date by June 2013)</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To measure serum IsoFs levels at different stages during hyperbaric therapy and observe the resultant trend</outcome>
      <timepoint>Weekly for a total of 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Patients currently booked for hyperbaric therapy to treat osteonecrosis secondary to radiation therapy
2.	18 years and over</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Active systemic infection / inflammatory disease
2.	Any risk factors for barotrauma
3.	Current steroid use</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/03/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. Tomas Corcoran</primarysponsorname>
    <primarysponsoraddress>Royal Perth Hospital
Anaesthetics Department
GPO Box X2213
Perth, WA 6001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Fremantle Hospital</fundingname>
      <fundingaddress>1/3 Alma Street  Fremantle Western Australia 6160</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr. Ed O'Loughlin</sponsorname>
      <sponsoraddress>Fremantle Hospital
Anaesthetics Department
Alma Street
Perth, WA 6160</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Isofurans are a group of compounds that are produced by the body when it is exposed to high levels of oxygen. It is a relatively new discovery (2002) and reflects the amount of stress to the body caused by exposure to oxygen. There is still a good deal we do not know about this subject, however it could be linked to a number of illnesses, including Parkinsons and certain types of lung and eye injuries. We aim to study the production of Isofurans under high oxygen pressures (hyperbaric), which has not been done before. The study will involve taking blood samples from patients who require hyperbaric treatment to improve bone production after radiotherapy, and monitoring the effect this has on Isofurans levels.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Metropolitan Area Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>PO Box 480 FREMANTLE WA 6959</ethicaddress>
      <ethicapprovaldate>20/12/2011</ethicapprovaldate>
      <hrec>1/11/0359</hrec>
      <ethicsubmitdate>1/12/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ed O'Loughlin</name>
      <address>Fremantle Hospital
1/3 Alma Street
Fremantle WA 6160</address>
      <phone>+61 8 9431 3333</phone>
      <fax />
      <email>edmond.o'loughlin@heath.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sonya Ting</name>
      <address>Fremantle Hospital
1/3 Alma Street  Fremantle Western Australia 6160</address>
      <phone>+61 8 9431 3333</phone>
      <fax />
      <email>sonyating@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sonya Ting</name>
      <address>Fremantle Hospital
1/3 Alma Street
Fremantle WA 6160</address>
      <phone>+61 8 9431 3333</phone>
      <fax />
      <email>sonyating@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>